首頁 > 市場調查報告書 > 製藥

疫苗

市場調查報告書

商品編碼

1736525

全球禽流感疫苗市場－按類型、株類型、應用、地區、預測分類的市場規模

Global Avian Influenza Vaccines Market Size By Type (Combination Vaccines, Inactivated Vaccines), By Strain-Type (H5 strain, H7 strain), By Application (Goose, Duck, Chicken), By Geographic Scope And Forecast

出版日期: 2025年05月05日 | 出版商:

Verified Market Research | 英文 | 商品交期: 2-3個工作天內

價格

簡介目錄

禽流感疫苗市場規模及預測

2024 年禽流感疫苗市場規模為 1.4014 億美元，預計到 2032 年將達到 1.9854 億美元，預測期內（2026-2032 年）的複合年成長率為 4.45%。

該報告對全球禽流感疫苗的市場佔有率、產量和銷售進行了深入分析。

推動全球禽流感疫苗市場發展的因素

禽流感疫苗市場的促進因素可能受到多種因素的影響。這些因素包括：

禽流感疫情加劇推動市場發展的主要因素之一是全球禽類和鳥類中禽流感疫情的增加。此類疫情對人類和動物族群構成威脅，因此對有效疫苗的需求也隨之增加。

政府措施和法規：為了遏制禽流感的蔓延，各國政府和國際組織實施了嚴格的立法和疫苗宣傳活動。這些項目為疫苗生產商創造了有利的環境，並促進了市場擴張。

家禽養殖業的擴張：禽流感疫苗的需求受到家禽養殖業擴張的影響，尤其是在新興經濟體。由於雞群數量的增加，農民加大了對疫苗接種的投入，以保護他們的牲畜，這支撐了市場的成長。

疫苗技術發展：隨著疫苗技術的不斷發展，包括更有效、更有效率的疫苗製劑、給藥方法和佐劑的開發，禽流感疫苗的安全性和有效性正在不斷提高。這些技術進步有可能吸引生產者和消費者，促進市場擴張。

認知與教育：市場擴張的一個關鍵驅動力是提高消費者、獸醫和家禽養殖戶對疫苗接種在預防禽流感疫情中價值的認知。疫苗接種率的提高得益於教育活動和資訊傳播計劃。

全球化與貿易：隨著禽類產品在國際貿易中的流通，禽流感在各國之間傳播的可能性很高。為了降低風險並確保貿易安全，許多國家已強制要求進出口禽類產品進行疫苗接種，導致全球對禽流感疫苗的需求增加。

限制全球禽流感疫苗市場的因素

禽流感疫苗市場面臨許多限制和挑戰，其中包括：

疫苗研發和生產成本高：禽流感疫苗研發和生產成本高昂，限制了市場擴張。這些成本使得疫苗對製造商和接種者來說都負擔不起，尤其是在偏遠地區。

農村地區疫苗取得受限：禽流感疫苗的分發和管理因取得問題而受到阻礙，尤其是在醫療設施不足的農村和偏遠地區。這些限制導致疫苗接種率低，並加劇了這些地區疫情的持續爆發。

疫苗安全性和有效性擔憂：儘管疫苗技術不斷進步，但人們對禽流感疫苗的安全性和有效性仍然存在疑慮。疫苗效力、病毒株突變以及潛在的副作用都可能威脅大眾對疫苗宣傳活動的信心，並阻礙市場擴張。

監管障礙和核准程序：禽流感疫苗繁瑣的監管規範和核准程序會延遲新產品的上市，並增加製造商的開發成本。這些法律障礙阻礙了新的競爭者進入市場，從而降低了創新和競爭。

全球經濟不確定性：禽流感疫苗的需求可能受到政府醫療預算和消費者購買習慣變化、經濟不穩定和國際市場波動的影響。經濟疲軟可能導致農業和醫療保健部門的預算削減，從而阻礙潛在的市場擴張。

抗原漂移和疫苗抗藥性風險：由於抗原漂移，禽流感病毒的日益增多威脅著疫苗的有效性。對現有疫苗產生抗藥性的病毒株的出現可能會降低疫苗的有效性，並且開發新的製劑和方法需要時間和成本。

Growing disease prevalence, rising demand for poultry for consumption, an increase in the number of outbreaks, and ongoing research for the development of efficient vaccinations for disease prevention are some of the important drivers driving market expansion. The Global Avian Influenza Vaccines Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Avian Influenza Vaccines Market Drivers

The market drivers for the Avian Influenza Vaccines Market can be influenced by various factors. These may include:

Growing Incidence of Avian Influenza Outbreaks: One major factor driving the market is the increase in avian influenza outbreaks among poultry and birds around the world. The need for efficient vaccines is increasing as these epidemics endanger human and animal populations.

Government Initiatives and Regulations: To stop the spread of avian influenza, governments and international organisations are putting in place stringent laws and immunisation campaigns. These programmes foster an atmosphere that benefits vaccine producers and propels market expansion.

Expanding Poultry business: The need for avian influenza vaccinations is influenced by the growing poultry business, especially in emerging economies. Farmers are investing more in vaccination to protect their animals as a result of greater populations of chickens being at risk, which is supporting market growth.

Developments in Vaccine Technology: The safety and efficacy of avian influenza vaccinations are improved by continuous developments in vaccine technology, which include the creation of more effective and efficient vaccine formulations, delivery methods, and adjuvants. Through their ability to draw in both producers and consumers, these technical advancements promote market expansion.

Awareness and Education: A key factor in the expansion of the market is raising consumer, veterinarian, and poultry farmer knowledge of the value of vaccination in averting avian influenza epidemics. Higher vaccination uptake rates are a result of education efforts and information-dissemination programmes.

Globalisation and Trade: As poultry products are traded internationally, there is a greater chance that avian influenza will spread between countries. Global demand for avian influenza vaccines has increased as a result of numerous nations requiring vaccination programmes for chicken imports and exports in order to reduce risk and guarantee trade safety.

Global Avian Influenza Vaccines Market Restraints

Several factors can act as restraints or challenges for the Avian Influenza Vaccines Market. These may include:

High Expenses of Vaccine Development and Production: The market's ability to expand is hampered by the high expenses incurred in the study, creation, and manufacturing of avian influenza vaccinations. These costs may make vaccines more expensive for both manufacturers and recipients, especially in underdeveloped areas.

Limited Accessibility in Rural locations: The distribution and administration of avian influenza vaccines are hampered by accessibility concerns, particularly in rural or distant locations with poor healthcare facilities. This restriction lowers vaccination uptake and adds to the ongoing outbreaks in these areas.

Vaccine Safety and Efficacy Concerns: Despite improvements in vaccine technology, questions remain regarding the safety and efficacy of avian influenza vaccinations. The efficacy of vaccines, variations in virus strains, and possible side effects can all threaten public trust in immunisation campaigns and impede market expansion.

Regulatory Obstacles and Approval Procedures: Extensive regulatory specifications and drawn-out approval procedures for avian influenza vaccinations can cause delays in the release of new products and raise development expenses for producers. These legal obstacles prevent new competitors from entering the market, which reduces innovation and competition.

Global Economic Uncertainty: The demand for avian influenza vaccines can be impacted by changes in government healthcare budgets, consumer buying habits, and economic instability and volatility in international markets. Economic downturns may result in budget cuts to the agriculture and healthcare sectors, which would hinder the potential for market expansion.

Risk of Antigenic Drift and Vaccine Resistance: Vaccine efficacy is threatened by the ongoing development of avian influenza viruses due to antigenic drift. The advent of strains resistant to current vaccinations may make them less effective, requiring the time-consuming and expensive development of new formulations and approaches.

Global Avian Influenza Vaccines Market Segmentation Analysis

The Global Avian Influenza Vaccines Market is segmented on the basis of Type, Strain Type, Application, And Geography.

Avian Influenza Vaccines Market, By Type

Combination Vaccines
Inactivated Vaccines
Live Recombinant Vaccines

Based on Type, The market is classified into Combination vaccines, Inactivated vaccines, and Live recombinant vaccines.

Avian Influenza Vaccines Market, By Strain-Type

H5 Strain
H7 Strain
H9 Strain

Based on Strain-Type, The market is classified into is segmented by H5 strain, H7 strain, and H9 strain.

Avian Influenza Vaccines Market, By Application

Goose
Duck
Chicken
Others

Based on Application, The market is classified into is segmented by Goose, Duck, Chicken, and Others.

Avian Influenza Vaccines Market, By Geography

North America
Europe
Asia Pacific
Rest of the world
On the basis of Geography, The market is classified into North America, Europe, Asia Pacific, and Rest of the world. APAC can keep ahead of the global Avian Influenza Vaccines Market growth curve. Increased avian influenza epidemics are to blame for the market's growth in the APAC region. Following the quick implementation of appropriate management strategies for avian influenza vaccine development, many government actions have been implemented to meet the emergent scenario. During the review period, the Avian Influenza Vaccines Market in Europe is expected to have the second-largest proportion of the global market. The surge in joint initiatives by regional governments and commercial entities to promote animal health could help to the market's growth.

Key Players

The major players in the Avian Influenza Vaccines Market are:
Merck & Co., Inc.
Boehringer Ingelheim GmbH
Zoetis Inc.
Ceva Sante Animale S.A.
Huvepharma, Inc.
Vencomatic Group B.V.
Aviva plc
Charles River Laboratories International, Inc.
Wuhan Biolake Biotechnology Co., Ltd.
Laboratorios HIPRA, S.A.QianYuanHao Biological Corporation Limite
Merial
Ringpu Bio-Technology Co. Ltd
Harbin Veterinary Research Institute (HVRI)
CEVA, Elanco, Zoetis, Inc.
FATRO S.p.A., Merck Animal Health (a subsidiary of Merck & Co. Inc.)
BoehringerIngelheim GmbH.

1 INTRODUCTION OF GLOBAL AVIAN INFLUENZA VACCINES MARKET

1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL AVIAN INFLUENZA VACCINES MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis

5 GLOBAL AVIAN INFLUENZA VACCINES MARKET, BY TYPE

5.1 Overview
5.2 Combination Vaccines.
5.3 Inactivated Vaccines
5.4 Live Recombinant Vaccines

6 GLOBAL AVIAN INFLUENZA VACCINES MARKET, BY STRAIN-TYPE

6.1 Overview
6.2 H5 Strain
6.3 H7 Strain
6.4 H9 Strain

7 GLOBAL AVIAN INFLUENZA VACCINES MARKET, BY APPLICATION

7.1 Overview
7.2 Goose
7.3 Duck
7.4 Chicken
7.5 Others

8 GLOBAL AVIAN INFLUENZA VACCINES MARKET, BY GEOGRAPHY

8.1 Overview
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
- 8.2.3 Mexico
8.3 Europe
- 8.3.1 Germany
- 8.3.2 U.K.
- 8.3.3 France
- 8.3.4 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Rest of Asia Pacific
8.5 Rest of the World
- 8.5.1 Latin America
- 8.5.2 Middle East & Africa

9 GLOBAL AVIAN INFLUENZA VACCINES MARKET COMPETITIVE LANDSCAPE

9.1 Overview
9.2 Company Market Ranking
9.3 Key Development Strategies

10 COMPANY PROFILES

10.1 QianYuanHao Biological Corporation Limited
- 10.1.1 Overview
- 10.1.2 Financial Performance
- 10.1.3 Product Outlook
- 10.1.4 Key Developments
10.2 Merial
- 10.2.1 Overview
- 10.2.2 Financial Performance
- 10.2.3 Product Outlook
- 10.2.4 Key Developments
10.3 Harbin Veterinary Research Institute (HVRI)
- 10.3.1 Overview
- 10.3.2 Financial Performance
- 10.3.3 Product Outlook
- 10.3.4 Key Developments
10.4 CEVA
- 10.4.1 Overview
- 10.4.2 Financial Performance
- 10.4.3 Product Outlook
- 10.4.4 Key Developments
10.5 Elanco
- 10.5.1 Overview
- 10.5.2 Financial Performance
- 10.5.3 Product Outlook
- 10.5.4 Key Developments
10.6 FATRO S.p.A.
- 10.6.1 Overview
- 10.6.2 Financial Performance
- 10.6.3 Product Outlook
- 10.6.4 Key Developments
10.7 Zoetis, Inc.
- 10.7.1 Overview
- 10.7.2 Financial Performance
- 10.7.3 Product Outlook
- 10.7.4 Key Developments
10.8 Ringpu Bio-Technology Co., Ltd
- 10.8.1 Overview
- 10.8.2 Financial Performance
- 10.8.3 Product Outlook
- 10.8.4 Key Developments
10.9 Merck Animal Health (a subsidiary of Merck & Co. Inc.)
- 10.9.1 Overview
- 10.9.2 Financial Performance
- 10.9.3 Product Outlook
- 10.9.4 Key Developments
10.10 Boehringer Ingelheim GmbH
- 10.10.1 Overview
- 10.10.2 Financial Performance
- 10.10.3 Product Outlook
- 10.10.4 Key Developments